Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02636036
Title Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors PsiOxus Therapeutics Ltd
Indications

salivary gland cancer

head and neck squamous cell carcinoma

bladder carcinoma

colorectal cancer

Therapies

Enadenotucirev + Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.